Terry Ann Burrell is Director of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 71,254 shares of RXRX, which is worth approximately $430,374. The most recent transaction as insider was on Jul 01, 2024, when has been sold 1,843 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 71.3K
0% 3M change
29.91% 12M change
Total Value Held $430,374

Terry-Ann Burrell Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 01 2024
BUY
Grant, award, or other acquisition
-
1,843 Added 2.52%
71,254 Class A Common Stock
Jun 03 2024
BUY
Grant, award, or other acquisition
-
13,097 Added 15.87%
69,411 Class A Common Stock
Apr 01 2024
BUY
Grant, award, or other acquisition
-
1,467 Added 2.54%
56,314 Class A Common Stock
Jul 13 2023
SELL
Open market or private sale
$104,182 $12.59 p/Share
8,275 Reduced 13.11%
54,847 Class A Common Stock
Jul 12 2023
SELL
Open market or private sale
$1,377,545 $12.67 p/Share
108,725 Reduced 63.27%
63,122 Class A Common Stock
Jun 16 2023
BUY
Grant, award, or other acquisition
-
12,612 Added 6.84%
171,847 Class A Common Stock
Jan 03 2023
BUY
Grant, award, or other acquisition
-
1,821 Added 1.13%
159,235 Class A Common Stock
Oct 03 2022
BUY
Grant, award, or other acquisition
-
1,265 Added 0.8%
157,414 Class A Common Stock
Jul 01 2022
BUY
Grant, award, or other acquisition
-
1,631 Added 1.03%
156,149 Class A Common Stock
Jun 14 2022
BUY
Grant, award, or other acquisition
-
18,145 Added 10.51%
154,518 Class A Common Stock
Apr 01 2022
BUY
Grant, award, or other acquisition
-
1,788 Added 1.29%
136,373 Class A Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
763 Added 0.56%
134,585 Class A Common Stock
Oct 01 2021
BUY
Grant, award, or other acquisition
-
629 Added 0.47%
133,822 Class A Common Stock
Jul 01 2021
BUY
Grant, award, or other acquisition
-
382 Added 0.29%
133,193 Class A Common Stock
Apr 20 2021
SELL
Other acquisition or disposition
-
126,561 Reduced 100.0%
0 Common Stock
Apr 20 2021
SELL
Conversion of derivative security
-
6,250 Reduced 100.0%
0 Common Stock
Apr 20 2021
BUY
Other acquisition or disposition
-
126,561 Added 50.0%
126,561 Class A Common Stock
Apr 20 2021
BUY
Conversion of derivative security
-
6,250 Added 4.49%
132,811 Class A Common Stock
Apr 16 2021
BUY
Grant, award, or other acquisition
-
6,250 Added 4.71%
126,561 Common Stock

Also insider at

BEAM
Beam Therapeutics Inc. Healthcare
TB

Terry Ann Burrell

Director
Cambridge, MA

Track Institutional and Insider Activities on RXRX

Follow RECURSION PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX